Presentation cardiac troponin and early computed tomography coronary angiography in patients with suspected acute coronary syndrome: a pre-specified secondary analysis of the RAPID-CTCA trial
Presentation cardiac troponin and early computed tomography coronary angiography in patients with suspected acute coronary syndrome: a pre-specified secondary analysis of the RAPID-CTCA trial
Aims: to evaluate the potential associations between presentation cardiac troponin and the clinical impact of early computed tomography coronary angiography (CTCA) in intermediate-risk patients with suspected acute coronary syndrome.
Methods and results: in a large multicentre randomized controlled trial of patients with intermediate-risk chest pain due to suspected acute coronary syndrome, early CTCA had no effect on the primary outcome-death or subsequent Type 1 or 4b myocardial infarction-but reduced the rate of invasive coronary angiography. In this pre-specified secondary analysis, cardiovascular testing and clinical outcomes were compared between those with or without cardiac troponin elevation at presentation. Of 1748 patients, 1004 (57%) had an elevated cardiac troponin concentration and 744 (43%) had a normal concentration. Patients with cardiac troponin elevation had a higher Global Registry of Acute Coronary Events score (132 vs. 91; P < 0.001) and were more likely to have obstructive coronary artery disease (59 vs. 33%; P < 0.001), non-invasive (72 vs. 52%; P < 0.001) and invasive (72 vs. 38%; P < 0.001) testing, coronary revascularization (47 vs. 15%; P < 0.001), and the primary outcome (8 vs. 3%; P = 0.007) at 1 year. However, there was no evidence that presentation cardiac troponin was associated with the relative effects of early CTCA on rates of non-invasive (Pinteraction = 0.33) and invasive (Pinteraction = 0.99) testing, coronary revascularization (Pinteraction = 0.57), or the primary outcome (Pinteraction = 0.41).
Conclusion: presentation cardiac troponin had no demonstrable associations between the effects of early CTCA on reductions in non-invasive and invasive testing, or the lack of effect on coronary revascularization or the primary outcome in intermediate-risk patients with suspected acute coronary syndrome.
570-579
Wang, Kang-Ling
b7aaf516-6761-48d9-aa55-ab913e722b41
Roobottom, Carl
1effc4a1-7b44-43de-af13-987777fe2ecf
Smith, Jason E.
93d47637-276c-4de4-b1af-013b16b60509
Goodacre, Steve
a4c9c41f-44a4-4de9-ac6d-7c4c0daa5b05
Oatey, Katherine
bf711588-c6f4-4032-ad33-9b743c4e25f2
O'Brien, Rachel
daa843a7-7fc6-4457-9882-60eff6396dde
Storey, Robert F.
892bb08c-5356-4fd8-a77c-2accce8e10f8
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Keating, Liza
a1c5f887-6f5d-4caa-b6d1-e1ebc5d3f507
Kardos, Attila
a23428f1-301f-4adb-b980-65f31dd9fef2
Felmeden, Dirk
116b66e8-a109-4172-ac5a-e72cc69fe2e7
Thokala, Praveen
6190c14b-72c4-4483-910c-b7ffc8c1a3f8
Mills, Nicholas L.
b013a4c9-7308-4fc0-8152-86c3e101444d
Newby, David E.
8684bf8c-1189-4f56-a666-c122bd9073c5
Gray, Alasdair J.
7f312647-2e4d-4fe8-847b-ad2cf464d75d
21 July 2022
Wang, Kang-Ling
b7aaf516-6761-48d9-aa55-ab913e722b41
Roobottom, Carl
1effc4a1-7b44-43de-af13-987777fe2ecf
Smith, Jason E.
93d47637-276c-4de4-b1af-013b16b60509
Goodacre, Steve
a4c9c41f-44a4-4de9-ac6d-7c4c0daa5b05
Oatey, Katherine
bf711588-c6f4-4032-ad33-9b743c4e25f2
O'Brien, Rachel
daa843a7-7fc6-4457-9882-60eff6396dde
Storey, Robert F.
892bb08c-5356-4fd8-a77c-2accce8e10f8
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Keating, Liza
a1c5f887-6f5d-4caa-b6d1-e1ebc5d3f507
Kardos, Attila
a23428f1-301f-4adb-b980-65f31dd9fef2
Felmeden, Dirk
116b66e8-a109-4172-ac5a-e72cc69fe2e7
Thokala, Praveen
6190c14b-72c4-4483-910c-b7ffc8c1a3f8
Mills, Nicholas L.
b013a4c9-7308-4fc0-8152-86c3e101444d
Newby, David E.
8684bf8c-1189-4f56-a666-c122bd9073c5
Gray, Alasdair J.
7f312647-2e4d-4fe8-847b-ad2cf464d75d
Wang, Kang-Ling, Roobottom, Carl, Smith, Jason E., Goodacre, Steve, Oatey, Katherine, O'Brien, Rachel, Storey, Robert F., Curzen, Nick, Keating, Liza, Kardos, Attila, Felmeden, Dirk, Thokala, Praveen, Mills, Nicholas L., Newby, David E. and Gray, Alasdair J.
,
RAPID-CTCA Investigators
(2022)
Presentation cardiac troponin and early computed tomography coronary angiography in patients with suspected acute coronary syndrome: a pre-specified secondary analysis of the RAPID-CTCA trial.
European heart journal. Acute cardiovascular care, 11 (7), .
(doi:10.1093/ehjacc/zuac057).
Abstract
Aims: to evaluate the potential associations between presentation cardiac troponin and the clinical impact of early computed tomography coronary angiography (CTCA) in intermediate-risk patients with suspected acute coronary syndrome.
Methods and results: in a large multicentre randomized controlled trial of patients with intermediate-risk chest pain due to suspected acute coronary syndrome, early CTCA had no effect on the primary outcome-death or subsequent Type 1 or 4b myocardial infarction-but reduced the rate of invasive coronary angiography. In this pre-specified secondary analysis, cardiovascular testing and clinical outcomes were compared between those with or without cardiac troponin elevation at presentation. Of 1748 patients, 1004 (57%) had an elevated cardiac troponin concentration and 744 (43%) had a normal concentration. Patients with cardiac troponin elevation had a higher Global Registry of Acute Coronary Events score (132 vs. 91; P < 0.001) and were more likely to have obstructive coronary artery disease (59 vs. 33%; P < 0.001), non-invasive (72 vs. 52%; P < 0.001) and invasive (72 vs. 38%; P < 0.001) testing, coronary revascularization (47 vs. 15%; P < 0.001), and the primary outcome (8 vs. 3%; P = 0.007) at 1 year. However, there was no evidence that presentation cardiac troponin was associated with the relative effects of early CTCA on rates of non-invasive (Pinteraction = 0.33) and invasive (Pinteraction = 0.99) testing, coronary revascularization (Pinteraction = 0.57), or the primary outcome (Pinteraction = 0.41).
Conclusion: presentation cardiac troponin had no demonstrable associations between the effects of early CTCA on reductions in non-invasive and invasive testing, or the lack of effect on coronary revascularization or the primary outcome in intermediate-risk patients with suspected acute coronary syndrome.
Text
zuac057
- Version of Record
More information
Accepted/In Press date: 9 May 2022
e-pub ahead of print date: 1 June 2022
Published date: 21 July 2022
Identifiers
Local EPrints ID: 492652
URI: http://eprints.soton.ac.uk/id/eprint/492652
ISSN: 2048-8726
PURE UUID: 48ec2733-1b8b-46ed-8b51-98f138f74af0
Catalogue record
Date deposited: 09 Aug 2024 16:42
Last modified: 10 Aug 2024 01:40
Export record
Altmetrics
Contributors
Author:
Kang-Ling Wang
Author:
Carl Roobottom
Author:
Jason E. Smith
Author:
Steve Goodacre
Author:
Katherine Oatey
Author:
Rachel O'Brien
Author:
Robert F. Storey
Author:
Liza Keating
Author:
Attila Kardos
Author:
Dirk Felmeden
Author:
Praveen Thokala
Author:
Nicholas L. Mills
Author:
David E. Newby
Author:
Alasdair J. Gray
Corporate Author: RAPID-CTCA Investigators
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics